Background The efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) differs in patients with lung adenocarcinoma harboring EGFR-activating …

Both epidermal growth factor receptor (EGFR) and RAS gene mutations contribute to the
development of non-small cell lung cancer (NSCLC). Because RAS is one of the …

Objectives Owing to novel therapy strategies in epidermal growth factor receptor (EGFR)-
mutated patients, molecular analysis of the EGFR and KRAS genome has become crucial …

Background The presence of mutation in EGFR gene is known as a predictive marker for the
response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) …

Introduction: Roughly one third of new non-small cell lung cancer (NSCLC) is diagnosed at
early stages. While lobectomy can improve mortality in this group, about 30–55% of patients …

Purpose: Mutations in epidermal growth factor receptor (EGFR) can be used to predict the
tumor response of patients receiving gefitinib for non–small cell lung cancer (NSCLC). We …

Background: We hypothesize that among patients with lung cancers the KRAS/EGFR
mutation profile and overall survival of collegiate smokers (former smokers who smoked …

Background The prognostic value of EGFR and KRAS mutations in resected non-small cell
lung cancer (NSCLC) has been reported. However, conflicting results were reported in these …

Purpose In the current targeted therapy era, information on the effect of smoking in
epidermal growth factor receptor (EGFR)-mutant lung cancer patients is scarce. Results In …

Lung cancers with an epidermal growth factor receptor (EGFR) gene mutation account for~
40% of adenocarcinomas in East Asians and~ 15% of those in Caucasians and African …